BR0013883A - Alvejamento de droga mediada por integrina - Google Patents
Alvejamento de droga mediada por integrinaInfo
- Publication number
- BR0013883A BR0013883A BR0013883-5A BR0013883A BR0013883A BR 0013883 A BR0013883 A BR 0013883A BR 0013883 A BR0013883 A BR 0013883A BR 0013883 A BR0013883 A BR 0013883A
- Authority
- BR
- Brazil
- Prior art keywords
- integrin
- drug targeting
- mediated drug
- cytostatic
- result
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 102000006495 integrins Human genes 0.000 title abstract 2
- 108010044426 integrins Proteins 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title 1
- 239000000824 cytostatic agent Substances 0.000 abstract 3
- 230000001085 cytostatic effect Effects 0.000 abstract 3
- 229940123038 Integrin antagonist Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Patente de Invenção: "ALVEJAMENTO DE DROGA MEDIADA POR INTEGRINA". A presente invenção diz respeito aos citostáticos que t~em a ação específica de tumor como um resultado da ligação de antagonistas de integrina <244>~v~<225>~3~ por meio de unidades de ligação preferidas. As unidades de ligação preferidas garantem estabilidade de soro do conjugado do citostático e do antagonista de integrina <244>~v<225>~3~ e ao mesmo tempo a ação intramolecular desejada em células tumorais como um resultado de sua capacidade de clivagem enzimática ou hidrolítica com a liberação de citostático.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39216799A | 1999-09-08 | 1999-09-08 | |
US60677200A | 2000-06-29 | 2000-06-29 | |
PCT/EP2000/008361 WO2001017563A2 (en) | 1999-09-08 | 2000-08-28 | Integrin-mediated drug targeting |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0013883A true BR0013883A (pt) | 2002-05-07 |
Family
ID=27013781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0013883-5A BR0013883A (pt) | 1999-09-08 | 2000-08-28 | Alvejamento de droga mediada por integrina |
Country Status (16)
Country | Link |
---|---|
US (1) | US20060189544A1 (pt) |
EP (1) | EP1235595B8 (pt) |
JP (1) | JP2003508497A (pt) |
CN (1) | CN1402643A (pt) |
AT (1) | ATE438413T1 (pt) |
AU (1) | AU773781B2 (pt) |
BR (1) | BR0013883A (pt) |
CA (1) | CA2383981A1 (pt) |
DE (1) | DE60042700D1 (pt) |
ES (1) | ES2330079T3 (pt) |
HU (1) | HUP0203899A3 (pt) |
MX (1) | MXPA02002488A (pt) |
NZ (1) | NZ517620A (pt) |
PL (1) | PL354268A1 (pt) |
RU (1) | RU2002109215A (pt) |
WO (1) | WO2001017563A2 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1219305A1 (en) * | 2000-12-27 | 2002-07-03 | Bayer Aktiengesellschaft | Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units |
EP1238678A1 (en) | 2001-03-08 | 2002-09-11 | Bayer Aktiengesellschaft | Enzyme-activated cytostatic conjugates with integrin ligands |
ITRM20040240A1 (it) * | 2004-05-13 | 2004-08-13 | Ist Naz Stud Cura Dei Tumori | Camptotecine coniugate in posizione 7 con antagonisti delle integrine. |
ITRM20040241A1 (it) * | 2004-05-13 | 2004-08-13 | Ist Naz Stud Cura Dei Tumori | Camptotecine coniugate in posizione 20 con antagonisti delle integrine. |
CN105566338B (zh) * | 2014-10-08 | 2017-11-21 | 兰州大学 | 一种喜树碱类化合物及其制备方法和用途 |
CN108456154A (zh) * | 2018-04-13 | 2018-08-28 | 昆明理工大学 | 一种n-叔丁氧羰基烃基胍的制备方法 |
WO2023057813A1 (en) * | 2021-10-04 | 2023-04-13 | Vincerx Pharma Gmbh | Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders |
WO2023057814A1 (en) * | 2021-10-04 | 2023-04-13 | Vincerx Pharma Gmbh | Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69322860T2 (de) * | 1992-04-03 | 1999-07-01 | Genentech Inc | Antikörper gegen alpha v beta 3 integrin |
EP0888381A4 (en) * | 1995-12-21 | 2001-10-17 | Scripps Research Inst | TARGETED THERAPEUTIC AND DIAGNOSTIC AGENTS, METHODS FOR THEIR PRODUCTION AND USE |
-
2000
- 2000-08-28 CN CN00814704A patent/CN1402643A/zh active Pending
- 2000-08-28 HU HU0203899A patent/HUP0203899A3/hu unknown
- 2000-08-28 MX MXPA02002488A patent/MXPA02002488A/es unknown
- 2000-08-28 AT AT00965901T patent/ATE438413T1/de not_active IP Right Cessation
- 2000-08-28 ES ES00965901T patent/ES2330079T3/es not_active Expired - Lifetime
- 2000-08-28 DE DE60042700T patent/DE60042700D1/de not_active Expired - Lifetime
- 2000-08-28 AU AU76487/00A patent/AU773781B2/en not_active Ceased
- 2000-08-28 WO PCT/EP2000/008361 patent/WO2001017563A2/en active Search and Examination
- 2000-08-28 CA CA002383981A patent/CA2383981A1/en not_active Abandoned
- 2000-08-28 NZ NZ517620A patent/NZ517620A/en unknown
- 2000-08-28 PL PL00354268A patent/PL354268A1/xx not_active Application Discontinuation
- 2000-08-28 BR BR0013883-5A patent/BR0013883A/pt not_active IP Right Cessation
- 2000-08-28 RU RU2002109215/15A patent/RU2002109215A/ru not_active Application Discontinuation
- 2000-08-28 JP JP2001521351A patent/JP2003508497A/ja active Pending
- 2000-08-28 EP EP00965901A patent/EP1235595B8/en not_active Expired - Lifetime
-
2006
- 2006-04-07 US US11/399,985 patent/US20060189544A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE60042700D1 (de) | 2009-09-17 |
HUP0203899A2 (hu) | 2003-02-28 |
EP1235595B8 (en) | 2009-10-07 |
PL354268A1 (en) | 2003-12-29 |
WO2001017563A2 (en) | 2001-03-15 |
CA2383981A1 (en) | 2001-03-15 |
EP1235595B1 (en) | 2009-08-05 |
JP2003508497A (ja) | 2003-03-04 |
ES2330079T3 (es) | 2009-12-04 |
US20060189544A1 (en) | 2006-08-24 |
MXPA02002488A (es) | 2002-08-12 |
AU7648700A (en) | 2001-04-10 |
WO2001017563A3 (en) | 2002-07-11 |
HUP0203899A3 (en) | 2004-09-28 |
NZ517620A (en) | 2004-02-27 |
RU2002109215A (ru) | 2003-12-10 |
EP1235595A2 (en) | 2002-09-04 |
CN1402643A (zh) | 2003-03-12 |
ATE438413T1 (de) | 2009-08-15 |
AU773781B2 (en) | 2004-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2353527A (en) | Adenosine A 3 receptor modulators | |
BRPI0113477B8 (pt) | proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula | |
AU3649397A (en) | Precise efficacy assay methods for active agents including chemotherapeutic agents | |
BR0010342A (pt) | Composto, droga, e, uso de composto da fórmula i ou ii | |
BR0312421A (pt) | Uso de inibidores de cept e opcionalmente inibidores hmg coa redutase e/ou agentes anti-hipertensivos | |
BR0109266A (pt) | Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto | |
DK0839026T3 (da) | Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler | |
BR0004382A (pt) | Partìculas revestidas de óxido misto de lìtio e sua utilização ii | |
DE69840165D1 (de) | Genkonstrukt das für ein heterologes "prodrug"-aktivierendes enzym und für ein zellgerichtes teil kodiert | |
BR9803704A (pt) | Quinazolina-4-ona como antagonistas do ampa. | |
BR9910458A (pt) | Fatores afetando a atividade de enzima de liberação de receptor de fator de necrose de tumor | |
BR0013883A (pt) | Alvejamento de droga mediada por integrina | |
BR9916423A (pt) | Formulação de baixo ponto de congelamento contendo fenol e/ou derivados de fenol | |
AU2002331356A1 (en) | Nanoparticles for dna administration to a target organ | |
BR9911978A (pt) | Feniluracilas substituìdas | |
ATE405294T1 (de) | Gezielt eingesetzte agenzien zur nervenregeneration | |
BR9810610A (pt) | Carboxamidas utilizáveis como agonistas 5-ht1f | |
PT1107793E (pt) | Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados | |
BR0107922A (pt) | Derivados de dibenzo[b,f]azepina e sua preparação | |
DE60229867D1 (de) | Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen | |
BR9814188A (pt) | "agonistas de 5-ht1f" | |
BR0009285A (pt) | Derivados de avermectina | |
DK1095032T3 (da) | Hidtil ukendte fluorescerende CYP2D-assayreagenser | |
TR200103827T2 (tr) | Farmakolojik kompleks | |
WO2006031718A3 (en) | Compositions and methods for modulating rank activities |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/55 (2017.01) |